Risk factors
Anixa Biosciences (ANIX) risk factors
Item 1A of every Anixa Biosciences Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors43 risks3 new2 dropped5 reworded
Accumulated deficit grew to $251,677,000 as of October 31, 2025, with cash reserves declining to $15,174,000.
Filed Jan 12, 2026 - FY2024 10-K risk factors42 risks
The company has accumulated losses of $240,750,000 as of October 31, 2024, with $19,924,000 in cash and investments. Therapeutics and vaccines remain pre-revenue, relying on partners like Moffitt and Cleveland Clinic. Risks focus heavily on early-stage biotechnology uncertainties, clinical trials, and dilution from future fundraising.
Filed Jan 10, 2025